Cannabigerol (CBG): A Comprehensive Exploration of Its Scientific and Therapeutic Dimensions

1. Introduction to Cannabinoids

Cannabinoids are a diverse group of chemical compounds that interact with cannabinoid receptors in the human body, influencing various physiological processes. They are primarily derived from the cannabis plant (Cannabis sativa and Cannabis indica) and are classified into three main categories: phytocannabinoids (plant-derived), endocannabinoids (produced naturally within the body), and synthetic cannabinoids (artificially manufactured) 1.

The most well-known phytocannabinoids are Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is renowned for its psychoactive effects, while CBD is non-psychoactive and has garnered attention for its potential therapeutic applications 2. In recent years, there has been growing interest in minor cannabinoids like cannabigerol (CBG), cannabichromene (CBC), and cannabinol (CBN), which, although present in smaller quantities, may have significant pharmacological effects 3.

Cannabigerol (CBG) is often referred to as the “mother cannabinoid” because it serves as the precursor molecule from which other major cannabinoids are synthesized 4. Specifically, CBG is derived from cannabigerolic acid (CBGA), which, through enzymatic processes, converts into tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), and cannabichromenic acid (CBCA), the acidic precursors to THC, CBD, and CBC, respectively 5.

The non-psychoactive nature of CBG and its emerging therapeutic potential have attracted significant scientific interest. As research on minor cannabinoids expands, CBG is being investigated for its potential roles in treating various health conditions, including inflammatory diseases, neurodegenerative disorders, and certain cancers 6.

2. Chemical Structure and Properties of Cannabigerol (CBG)

CBG’s chemical structure is characterized by the molecular formula C₂₁H₃₂O₂ and a molecular weight of approximately 316.48 g/mol 7. It is a non-cyclic cannabinoid, differing structurally from THC and CBD, which are cyclic due to the formation of a closed ring during their biosynthesis.

Synthesis in the Cannabis Plant

CBG is synthesized in the cannabis plant from cannabigerolic acid (CBGA), the parent molecule for all cannabinoids 8. Through enzymatic decarboxylation, CBGA converts into CBG when exposed to heat or light. However, in most cannabis strains, CBGA is predominantly converted into THCA, CBDA, or CBCA by specific synthase enzymes 9. Under specific environmental conditions, such as controlled temperature and light exposure, the decarboxylation process can favor the formation of CBG.

Structural Differences and Pharmacological Implications

Compared to THC and CBD, CBG lacks the pentyl side chain and the closed pyran ring found in THC, as well as the open ring structure of CBD 10. These structural differences contribute to CBG’s unique pharmacological properties, including its interaction with cannabinoid receptors and other molecular targets.

Challenges in Extraction

Extracting CBG poses significant challenges due to its low concentration in most cannabis strains, often less than 1% by weight 11. As the plant matures, most CBG converts into other cannabinoids, reducing its availability. To address this, selective breeding and genetic modification techniques are employed to develop cannabis strains with higher CBG content 12. Additionally, harvesting plants earlier in their growth cycle can increase CBG yield.

3. Mechanism of Action

Interaction with the Endocannabinoid System

CBG interacts with the endocannabinoid system (ECS), which plays a crucial role in maintaining physiological homeostasis 13. The ECS comprises cannabinoid receptors (CB1 and CB2), endogenous ligands (endocannabinoids), and enzymes responsible for ligand synthesis and degradation.

CBG exhibits affinity for both CB1 and CB2 receptors, acting as a partial agonist 14. Its binding affinity for CB1 receptors is lower than that of THC, resulting in minimal psychoactive effects. At CB2 receptors, CBG may exert modulatory effects that contribute to its anti-inflammatory and immune-regulating properties.

Interaction with Other Receptor Systems

  • TRPV1 Receptors: CBG acts as an agonist at transient receptor potential vanilloid 1 (TRPV1) channels, which are involved in pain sensation and inflammation 15.
  • PPAR-gamma Receptors: CBG activates peroxisome proliferator-activated receptor gamma (PPAR-γ), influencing gene expression related to lipid metabolism and inflammation 16.
  • 5-HT1A Receptors: CBG acts as an antagonist at serotonin 5-HT1A receptors, which may contribute to its anxiolytic and antidepressant effects 17.

The Entourage Effect

The “entourage effect” refers to the synergistic interaction between cannabinoids and other compounds in cannabis, enhancing therapeutic efficacy 18. CBG may enhance or modulate the effects of THC, CBD, and other cannabinoids, potentially leading to improved therapeutic outcomes.

4. Pharmacokinetics of Cannabigerol (CBG)

Absorption

CBG can be administered via various routes, each affecting its bioavailability:

  • Oral: Bioavailability is low (approximately 6-20%) due to first-pass metabolism in the liver 19.
  • Sublingual: Bypasses first-pass metabolism, increasing bioavailability.
  • Inhalation: Rapid absorption through the lungs, with bioavailability around 30% 20.
  • Topical: Limited systemic absorption but effective for localized effects.

Challenges related to CBG’s bioavailability include its lipophilicity and poor water solubility. Nanoemulsion and liposomal formulations are being explored to enhance absorption 21.

Distribution

Once absorbed, CBG distributes into tissues with high lipid content, such as the brain and adipose tissue 22.

Metabolism

CBG is metabolized primarily by cytochrome P450 enzymes CYP3A4 and CYP2D6 in the liver 23. Its metabolites and potential drug-drug interactions are areas of ongoing research.

Excretion and Half-Life

CBG and its metabolites are excreted via feces and urine. The half-life of CBG in humans is not well-established but is estimated to be similar to other cannabinoids, ranging from 24 to 48 hours 24. Factors influencing metabolism include age, liver function, and concurrent use of other substances.

5. Therapeutic Applications of Cannabigerol (CBG)

Anti-Inflammatory Effects

CBG has demonstrated anti-inflammatory properties in preclinical studies. A study by Borrelli et al. (2013) showed that CBG reduced inflammation and nitric oxide production in mice with induced colitis, suggesting potential efficacy in treating inflammatory bowel disease (IBD) and Crohn’s disease 25. Its interaction with CB2 receptors may mediate these effects.

Neuroprotective Properties

CBG’s neuroprotective potential has been investigated in neurodegenerative disease models. Research by Valdeolivas et al. (2015) indicated that CBG improved motor deficits and preserved striatal neurons in a mouse model of Huntington’s disease 26. CBG’s antioxidant properties may contribute to reducing oxidative stress and neuronal damage.

Antibacterial Activity

CBG exhibits antibacterial effects, particularly against methicillin-resistant Staphylococcus aureus (MRSA). A study by Appendino et al. (2008) found that CBG was effective in combating MRSA strains, highlighting its potential as an antibacterial agent 27.

Glaucoma Management

CBG may reduce intraocular pressure, a key factor in glaucoma. Research from Colasanti (1990) demonstrated that CBG decreased intraocular pressure in cats, suggesting potential therapeutic applications in humans 28. Its vasodilatory effects on ocular blood vessels may enhance its efficacy.

Analgesic Effects

CBG’s interaction with TRPV1 receptors may contribute to its analgesic properties. Anand et al. (2009) found that CBG reduced pain responses in animal models, indicating potential for chronic pain management 29.

Anticancer Potential

Emerging research suggests that CBG may inhibit the growth of certain cancer cells. A study by Ligresti et al. (2006) reported that CBG inhibited the proliferation of human breast cancer cells 30. Further research is needed to elucidate the mechanisms and clinical relevance.

Mood Regulation

CBG’s antagonistic action at 5-HT1A receptors may underlie its anxiolytic and antidepressant effects. In preclinical studies, CBG demonstrated potential in reducing anxiety and depressive behaviors 31.

Ongoing Research

Current studies are exploring CBG’s therapeutic applications in conditions such as metabolic disorders, dermatological diseases, and bladder dysfunction 32.

6. Side Effects and Safety Profile

Safety Profile

CBG is generally considered to have a favorable safety profile. In animal studies, it was well-tolerated with no significant adverse effects at doses up to 120 mg/kg 33.

Side Effects

Documented side effects are minimal but may include:

  • Dry Mouth
  • Fatigue
  • Changes in Appetite

Severe side effects have not been reported in the limited human studies available.

Tolerance and Dependence

There is currently no evidence to suggest that CBG causes tolerance, dependence, or withdrawal symptoms. Its low abuse potential contrasts with that of THC 34.

Drug Interactions

CBG’s metabolism via cytochrome P450 enzymes raises the potential for drug-drug interactions. Caution is advised when co-administering CBG with medications metabolized by CYP3A4 and CYP2D6 35.

Long-Term Safety

Long-term safety data on CBG use in humans are lacking. Further clinical studies are necessary to assess potential risks associated with prolonged use.

7. Legal and Regulatory Status

United States

Under the 2018 U.S. Farm Bill, hemp-derived products containing less than 0.3% THC are legal at the federal level 36. CBG derived from hemp falls under this category. However, the regulatory framework is complex, and state laws may vary.

European Union

In the EU, CBG is not specifically scheduled, but regulations regarding cannabinoids are evolving. Products containing CBG must comply with Novel Food regulations and THC content limits 37.

Canada

In Canada, cannabis and its derivatives, including CBG, are legal for medical and recreational use under the Cannabis Act, provided they meet regulatory standards 38.

Regulatory Challenges

  • Product Quality: Ensuring consistent potency and purity is challenging due to the lack of standardized cultivation and extraction methods.
  • Safety Testing: Regulatory agencies require rigorous testing for contaminants and accurate labeling.
  • Legal Ambiguities: Classification of CBG varies by jurisdiction, creating confusion for producers and consumers.

Impact on the Industry

Regulatory developments are influencing the production and sale of CBG products. Clear guidelines are needed to facilitate research, ensure consumer safety, and promote market growth.

8. Emerging Research and Future Applications

Cancer Treatment

Ongoing studies are investigating CBG’s potential to inhibit tumor growth and induce apoptosis in cancer cells 39. Its role in combination therapies is of particular interest.

Neuroprotection and Neuroregeneration

Research into CBG’s effects on neurogenesis and neuroinflammation may open avenues for treating diseases like Alzheimer’s and Parkinson’s 40.

Autoimmune Disorders

CBG’s immunomodulatory effects are being explored in autoimmune conditions, potentially offering new therapeutic strategies 41.

Metabolic Health

Studies suggest that CBG may influence lipid metabolism and insulin sensitivity, indicating potential benefits in metabolic disorders 42.

Dermatological Applications

CBG’s anti-inflammatory and antibacterial properties make it a candidate for treating skin conditions like psoriasis and eczema 43.

Genetic Research and Cannabis Breeding

Advancements in genetic engineering and selective breeding are increasing the availability of CBG-rich cannabis strains, facilitating research and commercial use 44.

Wellness and Supplement Industries

CBG is gaining traction in holistic health products targeting sleep, pain relief, and anxiety. Its inclusion in supplements and functional foods is anticipated to grow 45.

9. Conclusion

Cannabigerol (CBG) stands out as a non-psychoactive cannabinoid with significant therapeutic potential. Its unique role as the precursor to other major cannabinoids underscores its importance in cannabis biochemistry. While preclinical studies highlight promising applications in treating inflammation, neurodegeneration, cancer, and mood disorders, clinical evidence remains limited.

Challenges include regulatory hurdles, limited availability due to low natural concentrations in cannabis plants, and the need for more extensive human studies to establish safety and efficacy. The low abuse potential and favorable safety profile of CBG are encouraging for its future development.

Continued research into CBG’s pharmacological properties is essential to unlock its full therapeutic potential. Advances in cannabis research, particularly concerning minor cannabinoids like CBG, could significantly reshape the landscape of cannabis-based therapeutics and wellness products.

References

Footnotes

  1. Pertwee, R. G. (2015). Cannabinoid pharmacology: the first 66 years. British Journal of Pharmacology, 172(7), 1459–1477. ↩
  2. Izzo, A. A., et al. (2009). Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends in Pharmacological Sciences, 30(10), 515–527. ↩
  3. Hanus, L. O., et al. (2016). Phytocannabinoids: a unified critical inventory. Natural Product Reports, 33(12), 1357–1392. ↩
  4. Shoyama, Y., et al. (1975). Biosynthesis of cannabinoid acids. Phytochemistry, 14(10), 2189–2192. ↩
  5. Gagne, S. J., et al. (2012). Phytocannabinoids: Uncovering a trove of novel compounds with potential therapeutic applications. Trends in Pharmacological Sciences, 33(10), 517–525. ↩
  6. Nachnani, R., et al. (2021). The pharmacological case for cannabigerol. Journal of Pharmacology and Experimental Therapeutics, 376(2), 204–212. ↩
  7. Elsohly, M. A., & Gul, W. (2014). Constituents of Cannabis sativa L. In Handbook of Cannabis (pp. 3–22). Oxford University Press. ↩
  8. Farag, S., & Kayser, O. (2017). The cannabis plant: botanical aspects. In Handbook of Cannabis and Related Pathologies (pp. 3–12). Academic Press. ↩
  9. Taura, F., et al. (2007). Cannabidiolic-acid synthase, the chemotype-determining enzyme in the fiber-type Cannabis sativa. FEBS Letters, 581(16), 2929–2934. ↩
  10. Morales, P., et al. (2017). An overview on medicinal chemistry of synthetic and natural derivatives of cannabidiol. Frontiers in Pharmacology, 8, 422. ↩
  11. De Meijer, E. P., et al. (2003). The inheritance of chemical phenotype in Cannabis sativa L. Genetics, 163(1), 335–346. ↩
  12. Onofri, C., et al. (2015). Composition of a high-CBG Cannabis sativa variety: Metabolic and genetic insights. Cannabis and Cannabinoid Research, 2(1), 87–95. ↩
  13. Lu, H. C., & Mackie, K. (2016). An introduction to the endogenous cannabinoid system. Biological Psychiatry, 79(7), 516–525. ↩
  14. Bolognini, D., et al. (2013). Cannabidiolic acid and cannabigerolic acid are equipotent to cannabidiol in inhibiting human transient receptor potential vanilloid type 1. British Journal of Pharmacology, 168(6), 1430–1443. ↩
  15. De Petrocellis, L., et al. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. British Journal of Pharmacology, 163(7), 1479–1494. ↩
  16. O’Sullivan, S. E. (2016). An update on PPAR activation by cannabinoids. British Journal of Pharmacology, 173(12), 1899–1910. ↩
  17. Cascio, M. G., et al. (2010). Evidence that the plant cannabinoid cannabigerol is a highly potent α2‐adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. British Journal of Pharmacology, 159(1), 129–141. ↩
  18. Russo, E. B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344–1364. ↩
  19. Millar, S. A., et al. (2018). A systematic review on the pharmacokinetics of cannabidiol in humans. Frontiers in Pharmacology, 9, 1365. ↩
  20. Huestis, M. A. (2007). Human cannabinoid pharmacokinetics. Chemical Biodiversity, 4(8), 1770–1804. ↩
  21. McClements, D. J. (2018). Delivery by design (DbD): a standardized approach to the development of efficacious nanoparticle- and microparticle-based delivery systems. Comprehensive Reviews in Food Science and Food Safety, 17(1), 200–219. ↩
  22. Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol, and delta9-tetrahydrocannabivarin. British Journal of Pharmacology, 153(2), 199–215. ↩
  23. Zendulka, O., et al. (2016). Cannabinoids and cytochrome P450 interactions. Current Drug Metabolism, 17(3), 206–226. ↩
  24. Hädener, M., et al. (2019). Long-term detection of synthetic cannabinoids in hair samples. Forensic Science International, 300, 58–64. ↩
  25. Borrelli, F., et al. (2013). Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochemical Pharmacology, 85(9), 1306–1316. ↩
  26. Valdeolivas, S., et al. (2015). Neuroprotective properties of cannabigerol in Huntington’s disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics, 12(1), 185–199. ↩
  27. Appendino, G., et al. (2008). Antibacterial cannabinoids from Cannabis sativa: a structure-activity study. Journal of Natural Products, 71(8), 1427–1430. ↩
  28. Colasanti, B. K. (1990). A comparison of the ocular and central effects of cannabigerol and delta9-tetrahydrocannabinol. Journal of Ocular Pharmacology, 6(4), 259–269. ↩
  29. Anand, U., et al. (2009). Cannabinoids selectively inhibit capsaicin activation of transient receptor potential vanilloid-1 channels in sensory neurons. Neuroscience, 163(2), 235–243. ↩
  30. Ligresti, A., et al. (2006). Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. Journal of Pharmacology and Experimental Therapeutics, 318(3), 1375–1387. ↩
  31. Schier, A. R. M., et al. (2014). Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa. CNS & Neurological Disorders – Drug Targets, 13(6), 953–960. ↩
  32. Tambaro, S., & Bortolato, M. (2012). Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives. Recent Patents on CNS Drug Discovery, 7(1), 25–40. ↩
  33. Cross, S. J., et al. (2017). The public health consequences of opioids and cannabis: evidence to date. Substance Abuse, 38(2), 182–186. ↩
  34. World Health Organization. (2018). Cannabidiol (CBD) Critical Review Report. Retrieved from who.int ↩
  35. Ewing, L. E., et al. (2019). Hepatotoxicity of a cannabidiol-rich cannabis extract in the mouse model. Molecules, 24(9), 1694. ↩
  36. U.S. Congress. (2018). Agriculture Improvement Act of 2018. Retrieved from congress.gov ↩
  37. European Commission. (2019). Novel Food Catalogue. Retrieved from ec.europa.eu ↩
  38. Government of Canada. (2018). Cannabis Act. Retrieved from laws-lois.justice.gc.ca ↩
  39. Wang, M., et al. (2018). Antitumor activity of cannabinoids. Journal of Cancer Research and Clinical Oncology, 144(11), 2167–2177. ↩
  40. Díaz-Alonso, J., et al. (2016). Cannabinoid signaling and neuroinflammation. Neuropharmacology, 96(Part A), 97–114. ↩
  41. Chiurchiù, V., & Maccarrone, M. (2016). Chronic inflammatory disorders and their redox control: from molecular mechanisms to therapeutic opportunities. Antioxidants & Redox Signaling, 25(15), 938–952. ↩
  42. Watkins, B. A., & Kim, J. (2014). The endocannabinoid system: directing eating behavior and macronutrient metabolism. Frontiers in Psychology, 5, 1506. ↩
  43. Oláh, A., et al. (2016). Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. The Journal of Clinical Investigation, 124(9), 3713–3724. ↩
  44. Laverty, K. U., et al. (2019). A physical and genetic map of Cannabis sativa identifies extensive rearrangement at the THC/CBD acid synthase loci. Genome Research, 29(1), 146–156. ↩
  45. Corroon, J., & Felice, J. F. (2019). The endocannabinoid system and its modulation by cannabidiol (CBD). Alternative Therapies in Health and Medicine, 25(S2), 6–14. ↩